Skip to main content
Erschienen in: The European Journal of Health Economics 8/2020

16.04.2020 | Editorial

Should health technology assessment be more patient centric? If so, how?

verfasst von: Michael Drummond, Aleksandra Torbica, Rosanna Tarricone

Erschienen in: The European Journal of Health Economics | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Excerpt

Health technology assessment (HTA) methods and processes have been criticized for not being sufficiently ‘patient centric’. For example, Perfetto [1] argued that a proposed approach for assessing the value of health care interventions had not sufficiently incorporated a patient perspective and suggested that it represented a ‘missed opportunity’. A similar point was made about the other ‘value assessment frameworks’ developed recently in the United States [2]. In addition, Slejko et al. [3] proposed some key elements of a ‘patient informed’ reference case for conducting economic evaluations, which would supplement reference cases outlined by groups such as the second Panel on Cost-Effectiveness in Health and Medicine [4], by including consideration of elements such as convenience in receiving care, effects on the patient’s family, examination of whether quality of life instruments include the most relevant domains and a model structure for the economic evaluation that adequately reflects the patient’s journey through the various treatment options. …
Literatur
1.
Zurück zum Zitat Perfetto, E.M.: ISPOR’s initiative on US value frameworks: a missed opportunity for ISPOR and patients. Value Health 21(2), 169–170 (2018)CrossRef Perfetto, E.M.: ISPOR’s initiative on US value frameworks: a missed opportunity for ISPOR and patients. Value Health 21(2), 169–170 (2018)CrossRef
2.
Zurück zum Zitat Westrich, K.: Current landscape: value assessment frameworks. Washington, National Pharmaceutical Council, 2016 (www.npcow.org) Westrich, K.: Current landscape: value assessment frameworks. Washington, National Pharmaceutical Council, 2016 (www.​npcow.​org)
3.
Zurück zum Zitat Slejko, J., Mattingly, T.J., Mullins, C.D., Perfetto, E., dosReis, S.: Future of patients in healthcare evaluation: the patient-informed reference case. Value Health 22(5), 545–548 (2019)CrossRef Slejko, J., Mattingly, T.J., Mullins, C.D., Perfetto, E., dosReis, S.: Future of patients in healthcare evaluation: the patient-informed reference case. Value Health 22(5), 545–548 (2019)CrossRef
4.
Zurück zum Zitat Sanders, G.D., Neumann, P.J., Basu, A., et al.: Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 316, 1093–1103 (2016)CrossRef Sanders, G.D., Neumann, P.J., Basu, A., et al.: Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 316, 1093–1103 (2016)CrossRef
5.
Zurück zum Zitat Suarez-Almazor, M.E., Conner-Spady, B.: Rating of arthritis states bypatients, physicians, and the general public. Implications for cost-utility analysis. J Rheumatol 28, 648–656 (2001)PubMed Suarez-Almazor, M.E., Conner-Spady, B.: Rating of arthritis states bypatients, physicians, and the general public. Implications for cost-utility analysis. J Rheumatol 28, 648–656 (2001)PubMed
8.
Zurück zum Zitat Torbica, A., Tarricone, R., Drummond, M.F.: Does the approach to economic evaluation in health care depend on culture, values, and institutional context? Eur J Health Econom 19(6), 769–774 (2018)CrossRef Torbica, A., Tarricone, R., Drummond, M.F.: Does the approach to economic evaluation in health care depend on culture, values, and institutional context? Eur J Health Econom 19(6), 769–774 (2018)CrossRef
9.
Zurück zum Zitat Drummond, M., Tarricone, R., Torbica, A.: Assessing the added value of health technologies: reconciling different perspectives. Value Health 16(1), S7–S13 (2013)CrossRef Drummond, M., Tarricone, R., Torbica, A.: Assessing the added value of health technologies: reconciling different perspectives. Value Health 16(1), S7–S13 (2013)CrossRef
11.
Zurück zum Zitat Bijlmakers, L., Jansen, M., Boer, B., et al.: Increasing the legitimacy of tough choices in healthcare reimbursement: approach and results of a citizen forum in the Netherlands. Value Health 23, 32–38 (2020)CrossRef Bijlmakers, L., Jansen, M., Boer, B., et al.: Increasing the legitimacy of tough choices in healthcare reimbursement: approach and results of a citizen forum in the Netherlands. Value Health 23, 32–38 (2020)CrossRef
12.
Zurück zum Zitat Perfetto, E.M., Harris, J., Mullins, C.D., dosReis, S.: Emerging good practices for transforming value assessment: patients’ voices, patients’ values. Value Health 21(4), 386–393 (2018)CrossRef Perfetto, E.M., Harris, J., Mullins, C.D., dosReis, S.: Emerging good practices for transforming value assessment: patients’ voices, patients’ values. Value Health 21(4), 386–393 (2018)CrossRef
13.
Zurück zum Zitat Garrison, L., Neumann, P., Willke, R., Basu, A., Danzon, P., Doshi, J., Drummond, M.F., et al.: A health economics approach to US value assessment frameworks-summary and recommendations of the ISPOR special task force report [7]. Value Health 21, 161–165 (2018)CrossRef Garrison, L., Neumann, P., Willke, R., Basu, A., Danzon, P., Doshi, J., Drummond, M.F., et al.: A health economics approach to US value assessment frameworks-summary and recommendations of the ISPOR special task force report [7]. Value Health 21, 161–165 (2018)CrossRef
14.
Zurück zum Zitat Lakdawalla, D.N., Doshi, J.A., Garrison, L.P., Phelps, C.E., Basu, A., Danson, P.M.: Defining elements of value in health care–A health economics approach: An ISPOR special task force report [3]. Value Health 21, 131–139 (2018)CrossRef Lakdawalla, D.N., Doshi, J.A., Garrison, L.P., Phelps, C.E., Basu, A., Danson, P.M.: Defining elements of value in health care–A health economics approach: An ISPOR special task force report [3]. Value Health 21, 131–139 (2018)CrossRef
15.
Zurück zum Zitat Ciani, O., Federici, C.: Value lies in the eye of the patients: the why, what and how of patient-reported outcomes measures. Clin. Ther. 42(1), 25–33 (2020)CrossRef Ciani, O., Federici, C.: Value lies in the eye of the patients: the why, what and how of patient-reported outcomes measures. Clin. Ther. 42(1), 25–33 (2020)CrossRef
16.
Zurück zum Zitat Sarri, G., Kenny, J., Freitag, A., et al.: How frequently is patient experience formally assessed in health technology assessments? Results from a systematic literature review. Value Health 21(Suppl 3), S204 (2018)CrossRef Sarri, G., Kenny, J., Freitag, A., et al.: How frequently is patient experience formally assessed in health technology assessments? Results from a systematic literature review. Value Health 21(Suppl 3), S204 (2018)CrossRef
18.
Zurück zum Zitat Marsh, K., van Til J., Molsen-David E et al.: Health preference research in Europe: a review of its use in marketing authorization, reimbursement and pricing decisions. Value Health 2020 (in press) Marsh, K., van Til J., Molsen-David E et al.: Health preference research in Europe: a review of its use in marketing authorization, reimbursement and pricing decisions. Value Health 2020 (in press)
20.
Zurück zum Zitat National institute for Health and Care Excellence November: CG 32 Caesarian Section. NICE, London (2011 ) National institute for Health and Care Excellence November: CG 32 Caesarian Section. NICE, London (2011 )
21.
Zurück zum Zitat National institute for Health and Care Excellence August: NG 17 Type 1 Diabetes in Adults. NICE, London (2015) National institute for Health and Care Excellence August: NG 17 Type 1 Diabetes in Adults. NICE, London (2015)
22.
Zurück zum Zitat Drummond, M.F., Towse, A.: Orphan drugs policies: a suitable case for treatment. Eur J Health Econom 15(4), 335–340 (2014)CrossRef Drummond, M.F., Towse, A.: Orphan drugs policies: a suitable case for treatment. Eur J Health Econom 15(4), 335–340 (2014)CrossRef
23.
Zurück zum Zitat Cookson, R., Mirelman, A.J., Griffin, S., et al.: Using cost-effectiveness analysis to address health equity concerns. Value Health 20(2), 206–212 (2017)CrossRef Cookson, R., Mirelman, A.J., Griffin, S., et al.: Using cost-effectiveness analysis to address health equity concerns. Value Health 20(2), 206–212 (2017)CrossRef
Metadaten
Titel
Should health technology assessment be more patient centric? If so, how?
verfasst von
Michael Drummond
Aleksandra Torbica
Rosanna Tarricone
Publikationsdatum
16.04.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
The European Journal of Health Economics / Ausgabe 8/2020
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-020-01182-z

Weitere Artikel der Ausgabe 8/2020

The European Journal of Health Economics 8/2020 Zur Ausgabe